1. Home
  2. CUE vs SHMD Comparison

CUE vs SHMD Comparison

Compare CUE & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • SHMD
  • Stock Information
  • Founded
  • CUE 2014
  • SHMD 1864
  • Country
  • CUE United States
  • SHMD Germany
  • Employees
  • CUE N/A
  • SHMD N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • SHMD
  • Sector
  • CUE Health Care
  • SHMD
  • Exchange
  • CUE Nasdaq
  • SHMD Nasdaq
  • Market Cap
  • CUE 91.9M
  • SHMD 86.1M
  • IPO Year
  • CUE 2018
  • SHMD N/A
  • Fundamental
  • Price
  • CUE $1.49
  • SHMD $3.05
  • Analyst Decision
  • CUE Strong Buy
  • SHMD
  • Analyst Count
  • CUE 5
  • SHMD 0
  • Target Price
  • CUE $5.00
  • SHMD N/A
  • AVG Volume (30 Days)
  • CUE 254.0K
  • SHMD 64.6K
  • Earning Date
  • CUE 03-10-2025
  • SHMD 02-25-2025
  • Dividend Yield
  • CUE N/A
  • SHMD N/A
  • EPS Growth
  • CUE N/A
  • SHMD 1309.32
  • EPS
  • CUE N/A
  • SHMD 1.07
  • Revenue
  • CUE $9,532,000.00
  • SHMD $99,752,404.00
  • Revenue This Year
  • CUE $73.11
  • SHMD N/A
  • Revenue Next Year
  • CUE $11.02
  • SHMD N/A
  • P/E Ratio
  • CUE N/A
  • SHMD $2.84
  • Revenue Growth
  • CUE 149.53
  • SHMD N/A
  • 52 Week Low
  • CUE $0.45
  • SHMD $1.86
  • 52 Week High
  • CUE $2.37
  • SHMD $6.13
  • Technical
  • Relative Strength Index (RSI)
  • CUE 58.61
  • SHMD N/A
  • Support Level
  • CUE $1.22
  • SHMD N/A
  • Resistance Level
  • CUE $1.50
  • SHMD N/A
  • Average True Range (ATR)
  • CUE 0.12
  • SHMD 0.00
  • MACD
  • CUE 0.00
  • SHMD 0.00
  • Stochastic Oscillator
  • CUE 96.67
  • SHMD 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: